Chyle Leak After Pancreatoduodenectomy - Clinical Impact and Risk Factors in a Nationwide Analysis

By -

 

Executive Summary

This briefing document synthesizes the findings of a large-scale, nationwide observational cohort study conducted by the Dutch Pancreatic Cancer Group regarding chyle leak (CL) following pancreatoduodenectomy (PD). Based on data from 2,159 patients across 19 centers (2017–2019), the study validates the 2017 International Study Group for Pancreatic Surgery (ISGPS) definition of CL.

Critical Takeaways:

  • Incidence: The rate of clinically relevant (Grade B/C) chyle leak is 7.0%. Grade C leaks are extremely rare, occurring in only 0.1% of all patients.

  • Clinical Impact: CL is independently associated with a significantly prolonged hospital stay (OR 2.84) but does not increase in-hospital mortality.

  • Risk Factors: The primary independent predictors for developing CL are vascular resection (OR 2.1) and open surgery (OR 3.5).

  • Conclusion: While CL is a frequent complication, its clinical course is relatively mild in more than 98% of cases. The ISGPS definition provides a reliable framework for clinical assessment and future research.

Overview of Chyle Leak (CL)

Chyle leak is a complication caused by the disruption of abdominal lymphatics, specifically the main lymphatic vessels or the cisterna chyli located near the pancreatic head and neck.

ISGPS Definition and Classification

The International Study Group for Pancreatic Surgery (ISGPS) defines CL as the output of milky-colored fluid from a drain, wound, or drain site on or after postoperative day 3, with a triglyceride content of:

  • ≥ 110 mg/dL

  • ≥ 1.2 mmol/L

Severity Grading

The ISGPS classifies CL into three grades based on clinical impact:

Grade

Clinical Implications

Grade A

No therapeutic consequences; limited to oral dietary restrictions.

Grade B

Requires nasoenteral nutrition with dietary restriction, Total Parenteral Nutrition (TPN), percutaneous drainage, maintenance of surgical drains, or drug treatment (e.g., somatostatin analogs).

Grade C

Requires invasive in-hospital treatments, admission to the Intensive Care Unit (ICU), or results in mortality.


Analysis of Clinical Incidence and Impact

The nationwide analysis identified a total of 152 patients (7.0%) with Grade B/C CL.

Incidence Breakdown

  • Grade B: 6.9% (n=150)

  • Grade C: 0.1% (n=2)

  • Total Grade B/C: 7.0%

Correlation with Other Complications

CL frequently occurs in conjunction with other postoperative complications (48.6% of cases). The most common concurrent issues include:

  • Delayed Gastric Emptying (Grade B/C): 19.7%

  • Postoperative Pancreatic Fistula (POPF, Grade B/C): 15.9%

Impact on Hospitalization and Mortality

The presence of CL significantly extends the duration of hospital care but does not statistically impact survival rates.

  • Length of Stay (LOS): Patients with CL had a median LOS of 16 days, compared to 12 days for those without (P < 0.001). Multivariable analysis confirmed CL as an independent predictor of prolonged stay (>14 days).

  • Mortality: Mortality rates were 2.0% for patients with CL versus 2.7% for those without. There is no significant association between CL and in-hospital mortality (OR 0.3, P = 0.244).

Identification of Risk Factors

The study utilized multivariable logistic regression to isolate independent predictors of CL.

Significant Predictors

  1. Open Surgery (OR 3.5): This was identified as the strongest predictor. However, the study notes that this may be influenced by patient selection, as minimally invasive surgery is typically reserved for less advanced tumors without vascular involvement.

  2. Vascular Resection (OR 2.1): Both ISGPS type 1–2 and type 3–4 venous resections were identified as risk factors. Arterial resections were not significantly associated, though the sample size for arterial procedures was limited.

Non-Significant Factors

Several factors previously suggested as risks were not confirmed as independent predictors in this multivariable analysis:

  • Age, sex, and BMI.

  • Number of resected lymph nodes.

  • Aortocaval lymph node sampling.

  • Neoadjuvant therapy.

  • Concomitant postoperative pancreatic fistula (POPF).

Professional Insights and Discussion

Validation of the ISGPS Definition

The study provides the first nationwide validation of the ISGPS definition. The extremely low rate of Grade C leaks (only 1.3% of all CL cases) suggests that CL rarely becomes life-threatening. While some debate exists regarding whether to redefine Grade C to include TPN or drainage, the current classification remains consistent with other pancreatic complication definitions.

Management and Prevention

There is currently no global consensus on the management of CL. The ISGPS suggests a "step-up" approach:

  1. Dietary Modification: Long-chain triglyceride restriction or no-fat diets with medium-chain triglyceride (MCT) supplementation.

  2. Nutritional Support: Total Parenteral Nutrition (TPN) if dietary restrictions fail to decrease drain output.

  3. Invasive Intervention: Sclerotic embolization, peritoneovenous shunts, or operative ligation via lymphangiography for refractory cases.

Strategic Considerations

Because vascular resection is often necessary to achieve radical (R0) resection in the presence of portovenous involvement, the associated risk of CL is often an accepted surgical trade-off. Consequently, the focus shifts from prevention—which might compromise oncological outcomes—to specialized postoperative management and follow-up.

Study Limitations

The findings are subject to the limitations of retrospective analysis, including potential selection bias regarding surgical approach and missing data on specific management techniques (e.g., use of octreotide or specific enteral feeding protocols) not captured in the mandatory audit.